Cargando…

Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study

PURPOSE: To investigate (in a post hoc analysis of the 2-year CONDUCT study) the characteristics and clinical outcomes of men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression who benefitted from lifestyle changes alone. METHODS: Patients were given lifestyle advi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roehrborn, Claus G., Oyarzabal Perez, Igor, Roos, Erik P. M., Calomfirescu, Nicolae, Brotherton, Betsy, Palacios, Juan Manuel, Vasylyev, Averyan, Manyak, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332489/ https://www.ncbi.nlm.nih.gov/pubmed/27334136 http://dx.doi.org/10.1007/s00345-016-1884-5

Ejemplares similares

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo‐controlled study
por: Rosen, Raymond C., et al.
Publicado: (2018)

Men’s Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo‐controlled study
por: Roehrborn, Claus G., et al.
Publicado: (2020)

Model‐based meta‐analysis of individual International Prostate Symptom Score trajectories in patients with benign prostatic hyperplasia with moderate or severe symptoms
por: D'Agate, Salvatore, et al.
Publicado: (2020)

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms
por: D'Agate, Salvatore, et al.
Publicado: (2021)

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
por: Roehrborn, Claus G, et al.
Publicado: (2008)

Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia
por: McVary, Kevin T., et al.
Publicado: (2021)

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Shore, Neal, et al.
Publicado: (2019)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

Which is the Best Laser for Treatment of Benign Prostatic Hyperplasia?
por: Scoffone, Cesare Marco, et al.
Publicado: (2022)

Serum Dioxin, Testosterone, and Subsequent Risk of Benign Prostatic Hyperplasia: A Prospective Cohort Study of Air Force Veterans
por: Gupta, Amit, et al.
Publicado: (2006)

Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia
por: Agbugui, Jude Orumuah, et al.
Publicado: (2016)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

AB016. Which laser works best for benign prostatic hyperplasia?
por: Kim, Sae Woong
Publicado: (2015)

Literature review of lupus nephritis From the Arabian Gulf region
por: Al-Shujairi, Arwa, et al.
Publicado: (2022)

Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia
por: Bouza, Carmen, et al.
Publicado: (2006)

Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?
por: Bid, Hemant Kumar, et al.
Publicado: (2010)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia
por: Madigan, Allison A., et al.
Publicado: (2012)

Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches
por: Li, Shao, et al.
Publicado: (2010)

Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey
por: Ertel, Phillip, et al.
Publicado: (2016)

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH
por: D’Agate, Salvatore, et al.
Publicado: (2019)

Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression
por: D’Agate, Salvatore, et al.
Publicado: (2020)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

Correction to: Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Benign Prostatic Hyperplasia
Publicado: (2015)

Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia
por: Hong, Heeok, et al.
Publicado: (2009)

Bipolar transurethral enucleation of prostate versus photoselective vaporization for symptomatic benign prostatic hyperplasia (>70 ml)
por: Mu, Xiao-Nan, et al.
Publicado: (2017)

Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review
por: Sun, Fei, et al.
Publicado: (2020)

Benign Prostatic Hyperplasia: from Bench to Clinic
por: Yoo, Tag Keun, et al.
Publicado: (2012)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia
por: Dixon, Christopher M, et al.
Publicado: (2016)

Evaluation of outcome of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia: A 10-year experience
por: Haroun, Hossam, et al.
Publicado: (2019)

Bipolar Transurethral Enucleation of the Prostate: Is it a size-independent endoscopic treatment option for symptomatic benign prostatic hyperplasia?
por: Bebi, Carolina, et al.
Publicado: (2021)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Analysis of Initial Baseline Clinical Parameters and Treatment Strategy Associated with Medication Failure in the Treatment of Benign Prostatic Hyperplasia in Korea
por: Choi, Hoon, et al.
Publicado: (2010)

Prostatic Artery Embolization as a Treatment Option for Symptomatic Benign Prostatic Hyperplasia: Results from the Prospective Follow-Up Study in Lithuania
por: Jankauskas, Tautvydas, et al.
Publicado: (2023)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms
por: Black, Libby, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_rfhjrbqjv6e3bbv01j02ipkjbu